ClinicalTrials.Veeva

Menu

CVP-guided Aquapheresis for the Treatment of Acute Congestion in Heart Failure (Aquadex)

H

Heinrich-Heine University, Duesseldorf

Status

Completed

Conditions

Heart Failure

Treatments

Procedure: Ultrafiltration

Study type

Observational

Funder types

Other

Identifiers

NCT02079259
Aquadex

Details and patient eligibility

About

The number of patients with acute congestion on chronic heart failure is increasing. Ultrafiltration has recently been proposed as an alternative approach for the stabilization of volume balance, especially in patients with imminent diuretic resistance.

There is increasing evidence that ultrafiltration may relief cardiac congestion with lesser effects on blood pressure and activation of renin angiotensin system, respectively . However, recent studies revealed conflicting results: demonstration the superiority of ultrafiltration in comparison to diuretic treatment, and a lack of evidence of benefit, as well as an excess of adverse events with ultrafiltration.

Aquapheresis with adapted ultrafiltration rate guided by central venous pressure is safer than aquaphesis with a constant ultrafiltration with comparable effectiveness

Enrollment

9 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with chronic heart failure scheduled for LVAD
  • Indication for CVVH/Aquapheresis

Exclusion criteria

  • Renal Disease (GFR <20 ml / min)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems